The drug selection process in our International Linked Clinical Trials (iLCT) programme is governed and evaluated by a committee of world leading scientists, physicians and advocates, all experts in their field of Parkinson’s research.

The iLCT Committee

Learn More

Patrik Brundin, M.D., Ph.D. (Scientific Committee chair)

Learn More

Professor Roger Barker

Learn More

Dr Camille Carroll

Learn More

Tom Folytnie, Ph.D.

Learn More

David Devos, Ph.D.

Learn More

Ted Dawson, M.D., Ph.D.

Learn More

Brian Fiske, Ph.D.

Learn More

Caroline Tanner, M.D., Ph.D., F.A.A.N.

Learn More

Mark R. Cookson, Ph.D.

Learn More

Tim Greenamyre, M.D., Ph.D.

Learn More

Howard Federoff, M.D., Ph.D.

Learn More

Karl Kieburtz, M.D., MPH

Learn More

Dimitri Krainc, M.D.

Learn More

Andrew Lees, F.R.C.P., FMedSci

Learn More

Mark Mattson, Ph.D.

Learn More

Michael Schwarzschild, M.D., Ph.D.

Learn More

David Simon, M.D.

Learn More

David Sulzer, M.D.

Learn More

John Trojanowski, M.D.

Learn More

Director of Research and Development
Dr Richard Wyse

Learn More

Deputy Director of Research
Dr Simon Stott

Learn More

Flint Beal, M.D.

Note: Very sadly, iLCT committee member, Professor M. Flint Beal, died in June 2021.  Flint was former chair of the Department of Neurology and Neuroscience at Weill Cornell Medicine, and neurologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center and the University Professor of Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine.  He was an internationally recognized leader in neurology and neurodegenerative disorders and one of the greatest clinician-scientists of his generation.